. While between-hospital variability in procedure use was larger in USA, the risk of dying in a high relative to a low mortality hospital (hospitals in percentiles 95 and 5) was 2.65 in Portugal when in USA was only 1.03. Conclusions: Although in-hospital mortality due to an AMI improved in both countries, patient management in USA seems more effective and alarming disparities in quality of care across hospitals are more likely to exist in Portugal.
countries but CABG decreased only in the USA (USA:
Introduction
Different health systems have varying abilities to adopt new health technologies with potential impact on their healthcare performance. Particularly when these have been proven to be cost-effective compared to other therapeutic alternatives. Reasons for the differences are likely related to variations in regulatory processes that approve new technologies, in healthcare practice patterns, and in the organization and economic capacity of health systems to provide new treatments [1] [2] [3] [4] [5] . As such, differences may be even more apparent between the USA and countries in Europe, which significantly contrast in their gross domestic products, regulatory framework of new medical device approval, capacity to adopt and diffuse new health technology, and population epidemiological profiles [6] [7] [8] . Moreover, although controversial, the WHO ranked the health system of the US behind many of its counterparts in Europe, reflecting its incapacity to transform higher per capita expenditure in healthcare in proportional higher accessible quality of care when compared to most European countries [9] .
Acute myocardial infarction (AMI) is a common, fatal and costly disease. Despite significant declines in mortality during the last decade notably as a result from the advent of new health technologies it remains a considerable societal burden [10] [11] [12] [13] . Therefore, regular monitoring is of crucial importance. Several observational studies compared AMI management between the USA and European countries [1, 2, 4, 7, 11, 14, 15] , however, little is known about how different countries compare regarding within-country disparities in healthcare quality in AMI treatment across hospitals. According to previous findings AMI patients in the USA are more frequently subject to invasive coronary procedures, face fewer in-hospital deaths, shorter hospital stays and more readmissions when compared to European countries. However, two studies observed no significant differences between USA versus Sweden in survival after an AMI in adults [1, 3] , and vital statistics data indicate that AMI mortality per capita in the USA is comparable to European average.
In this study, we sought to characterize AMI incidence, hospital management, and outcomes in the two sides of the Atlantic using comparable inpatient hospitalizations data covering the period between 2000 and 2010 from Portugal and the USA exploring for potential differences in inter-hospital disparities within countries. We chose this period because it encompassed important advances in AMI treatment [2] . We chose Portugal because performance of its health system has been ranked ahead of the health system of the USA (12th vs. 37th); [9] Portugal saw one of the most enthusiastic adoption rates of the drug-eluting stent (DES) per percutaneous coronary intervention (PCI) in Europe [16] followed by an increase in PCI use that eventually became the preferred therapy in elevated ST-segment AMI management when compared to thrombolysis; and AMI death rates in Portugal are comparable to the average rate of European countries [10, 17, 18] thus making it a interesting candidate for transatlantic comparisons of AMI management and outcomes.
Material and Methods

Data sources
Portugal data We used billing information for all public sector hospitalizations in Portugal occurring between 1 January 2000 and 31 December 2010. These data were obtained from the Administração Central do Sistema de Saúde, IP (ACSS) in Portugal and represent~85% of all Portuguese hospital inpatient discharges [19] .
US data
The Nationwide Inpatient Sample (NIS) with hospitalizations occurring over the same period in the USA was obtained from the Health Care Utilization Project (HCUP), made available by the Agency for Healthcare Research and Quality (detailed information is available at https://www.hcup-us.ahrq.gov/nisoverview.jsp). This is the largest publicly available all-payer inpatient healthcare database in the USA, containing a nationwide representative 20% stratified random sample of discharges from short-term non-federal American hospitals.
Comparability of data sets
Billing data from the two countries consist of similar diagnosis and procedure codes (based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)), including primary and secondary diagnoses, type of admission and discharge status, patient demographic characteristics, length of stay (LOS), severity metrics and comorbidity measures. The majority of the variables included in the data have equivalent definitions and coding levels between the two countries with some minor differences. The number of potential diagnosis or procedure codes is 15 in the USA and 20 in Portugal, no race/ethnicity information is available for Portugal, 'urgent' and 'emergency' are different types of admission in the USA but used interchangeably in Portugal, and inpatient hospitalization is defined as an over-night or longer stay in the USA while in Portugal is defined as a 24-h or longer stay.
Patient population
We identified adults aged 20 years or older at admission, discharged alive or dead with a primary diagnosis of a new AMI. Discharges for ST-segment elevation myocardial infarction (STEMI) and non-STEMI were further identified based on the primary diagnosis (ICD-9-CM codes available in Supplementary data Table S1 ) [20] . We excluded hospitalizations of patients discharged alive in the same day of admission or who left against medical advice because they are unlikely to have had an AMI [21, 22] . Admissions associated with zero charges (USA) or invalid discharges identified by duplicate data in all variables of the database (Portugal) were also excluded. Moreover, patients discharged to hospice were also excluded using a Discharge Disposition variable available in both data sources given that this disposition status may miss to classify episodes with adverse outcome [22] . Finally, hospitalizations with missing values in variables for gender, patient disposition status at discharge and LOS were further excluded given that they are used as predictor or outcome variables.
Patient characteristics
To characterize the cohorts, we identified demographic, risk factors and comorbidities utilizing US' Centers for Medicare and Medicaid Services (CMS) AMI hospital mortality assessments codes, selecting 27 risk factor and comorbid conditions variables proposed by Krumholz et al. [21] . to profile hospitals based on 30-day mortality rates in patients with AMI (see Supplementary data Table S5 ) [21] . The variables utilized by the CMS have shown superior predictive capacity of outcomes when compared with several severity scores [23] . Moreover, while these are based on cohorts aged 65 or older at the time of their AMI, they have been also utilized in younger populations [24] . All discharges were included, regardless of admission path. In particular, patients transferred in or out of hospital were included in all analyses as separate hospitalizations given that patient id was not traceable.
In-hospital procedures and outcomes
Annual hospitalization rates were computed over all, and separately for STEMI and Non-STEMI discharges. In-hospital cardiac catheterization, PCI, coronary artery bypass graft (CABG) surgery, valve procedures and pacemaker/heart assist/defibrillation-related procedures were identified based on ICD-9-CM codes documented in the procedures variables (see Supplementary data Table S1 ). During our observational period, several new technologies were introduced. Coronary brachytherapy was introduced in early 2001 simultaneously in the USA and in Portugal; and trials indicating no differences between CABG performed on-and off-pump appeared in the early 2000s for low risk patients and in 2010 for high-risk patients [25, 26] . While drug-eluting coronary stents were approved in the US in 2003 and a year earlier in Europe, coding inaccuracies in the Portugal database prevented a comparative assessment. To minimize this pitfall, we identified implantation of coronary stents, either bare-metal stents or DES.
Two in-hospital outcomes were assessed: in-hospital mortality, regardless of cause and hospital LOS operationalized as the date of discharge minus the date of admission plus one.
Statistical analyses
The data use policy prohibited sharing of discharge-level data between Portugal and the USA. We thus adopted a distributed computing and modeling approach. Statistical summaries (frequencies, percentages, means, standard errors (SE) and sample sizes) were distributed between the two research teams.
We were unable to analyze the data at the patient level because we were working with a 20% random sample of inpatient discharges for the US and patient identification in Portugal is only available within the same hospital and year of discharge. Therefore, the unit of analysis considered throughout the analysis is hospital discharge.
Unadjusted procedure, diagnoses and mortality rates, and mean LOS (MLOS) were calculated for each country. For betweencountry comparison, age-sex-adjusted rates, rate ratios and mean difference (Portugal relative to the US) were estimated using the 2010 US population as the reference population (Supplementary  data Table S2 ) [27] considering 10-year age intervals or wider-range age intervals in the case of low-frequency events. All estimates for the US data were computed using discharge weights to account for the complex design sampling of the NIS.
Within-country risk-adjusted procedure rates were estimated using hierarchical logistic regression separately for each country where random intercepts were included to account for correlation among patients treated at the same hospitals. The random intercepts were assumed to arise from a normal distribution [28] . We included patient demographic information (including an age and sex interaction effect) whether the admission status was classified as emergent/urgent, risk factor, comorbidity and year of discharge in the model. Because in-hospital mortality was observed, rather than 30-day mortality, risk-adjusted in-hospital hazard ratios were estimated. We used semi-parametric shared frailty models considering the same independent variables as before [Model 1], in which the frailty parameter was assumed to arise from a one-parameter Gamma distribution and was included to account for withinhospital data correlation [28] . We extended this model with predictor variables for revascularization procedures (PCI or CABG) to obtain risk-adjusted in-hospital mortality rates per procedure and assess between-hospital variability in in-hospital mortality after adjusting for therapeutic management [Model 2]. Between-hospital variability modeled through hierarchical logistic regression was summarized as 2 times the square root of the between-hospital variance component and then exponentiated. This corresponds to a change in the odds of the event for an increase of ±1 standard deviation of the mean hospital rate. Between-hospital variability modeled through shared frailty models was summarized as the ratio between the hazard of dying in the hospital denoted by the 95 percentile of the oneparameter gamma distribution and the hazard of dying in the hospital denoted by percentile 5. This corresponds to the risk of a patient dying in hospital when treated in a high-mortality hospital relative to being treated in a low mortality hospital.
Results
Study populations
In 2010, the US population was 309.3 million, 13% was aged 65 years or older, and 16.3% had no health insurance; the 2010 Portuguese population was 10.6 million, 19% aged at least 65 years, and universal healthcare coverage (see Supplementary data Table S3 ). We identified a total of 1 566 601 AMI hospitalizations: 123 442 in Portugal from 83 hospitals and 1 443 159 in the USA from 3853 hospitals representing 7 084 136 AMI patients nationwide (Fig. 1, Table 1 ). Compared with the USA, AMI hospitalizations in Portugal of female patients and of elderly patients were less common, there were more emergent/urgent admissions, and more were likely to be STEMI admissions (Table 1) . Comorbid conditions were higher in the US-the single exception was cerebrovascular disease (3.5% in Portugal versus 3.0% in the USA).
Principal findings
Crude hospitalization rates declined in the USA but increased in Portugal ( Table 2 ). The age-sex adjusted AMI hospitalization rates decreased from 27 per 1000 person-years in 2000 to 19 in 2010 in the USA (RR = 0.695; 95% CI = [0.693, 0.696]) but increased in Portugal (11 to 13, RR = 1.16 [1.12, 1.19] ). These patterns were driven by a decrease of STEMI hospitalizations in the USA and an increase of Non-STEMI hospitalizations in Portugal (Fig. 2) . Moreover, age-sex adjusted Non-STEMI hospitalization rates were more prevalent than STEMI hospitalizations in the USA but less prevalent in Portugal (Fig. 2) .
Crude procedure rates (Table 2) . Of those undergoing CABG surgery, off-pump use increased between 2000 and 2010 in Portugal, and was higher in Portugal compared with the USA. PCI use increased annually in both countries. Use of coronary stents was high in the USA and remained high throughout our study period. The crude rate of stenting more than doubled in Portugal. Adjusted rates (Table 3) indicated females had lower odds of undergoing revascularization compared with males regardless of country. Between-hospital variability in procedure use was lower in Portugal compared with the USA. For instance, the odds of undergoing PCI in a moderately high PCI hospital (+1 Standard Deviation) was nearly 19 times that when admitted to a moderately low PCI hospital in Portugal; in the US, these odds were more than 250.
Mean hospital LOS (MLOS) decreased in both countries. However, longer MLOS were observed in Portugal (mean difference 2.77 [2.73, 2.82] in 2010), being longer among survivors when compared to non-survivors in Portugal and shorter in the USA. Females had a higher risk of in-hospital mortality following AMI compared with males in both countries but this disparity was negligible in the USA (Table 4 ). Annual declines in mortality were observed in both countries and in-hospital revascularization strategies increased survival to discharge. However, the effectiveness of these strategies was much larger in Portugal (Table 4) . Between-hospital variation in mortality was smaller in the USA relative to Portugal-the hazard of dying in a high-mortality US hospital was essentially no different than that in a modestly low mortality hospital, the hazard ratio was equal to 1.03; in Portugal, this hazard ratio was 2.65.
Discussion
International comparisons may yield insights on healthcare expectations of patients exposed to different medical care practice patterns. With this in mind, we produced a comprehensive analysis about AMI patient management across contrasting healthcare systems in the two sides of the Atlantic. Our results show substantial differences between the two countries regarding incidence of AMI hospitalizations, risk profiles of patients, and in-hospital revascularization strategies use, particularly in earlier years of the study's reporting period. Higher procedures use rates in the USA were accompanied by significantly lower mortality and shorter stays when compared to Portugal. However, substantial differences were also found in the risk profiles of the two populations in the two countries. Although AMI events were more likely to occur in the USA than in Portugal, age-sex-adjusted STEMI rates in Portugal remained stable throughout the study period while they declined in the USA (Fig. 2) . Therefore, and since STEMI events are associated with worse prognosis when compared to Non-STEMI, this risk pattern may aid to explain why Portugal exhibited higher in-hospital mortality than the US. Given that primary PCI is the recommended reperfusion therapy in STEMI [29] , a large incidence of STEMI hospitalizations would anticipate a high PCI use rate. However, differences in STEMI rates were not mirrored by statistically significant different PCI use rates in 2010 between the two countries. Being PCI a complex and expensive procedure, countries with lower economic Table 1 with the exception of Race/Ethnicity. capacity, such as Portugal, are likely to experience more constraints in its use. On the other hand, the general belief that PCI use is helpful even in less acute manifestations of AMI associated with higher economic capacity, such as the US, is also likely to further aggravate the difference (or lack of difference) between practice patterns in these countries [30] . In fact, in 2010 the USA had nearly double the number of hospitals per capita with cardiac catheterization facilities and four times the number of hospitals per capita with cardiothoracic surgery services, which is in line with the revascularization procedures utilization rates ratios observed in this study [2] .
Furthermore, while unadjusted and risk-adjusted analysis show that both countries saw a decline in in-hospital mortality throughout the period, these results also indicate that there was a larger increase in the use of PCI and CABG procedures in Portugal. Since the hazard ratio for annual change in the extended frailty model [Model 2], which included additional predictor variables to control for PCI and CABG use, increased for Portugal when compared to the same hazard ratio in the base frailty model [Model 1], which only included patient characteristics as predictors variables, the larger uptake on revascularization procedures seems to have contributed for the inhospital mortality reduction in Portugal.
Our findings regarding STEMI trends are consistent with those reported by others for Portugal and USA using independent data sources as well as other studies covering transatlantic comparisons which also observed lower relative weight of STEMI cases in AMI hospitalizations in the USA when compared to the EU [4, 20, [31] [32] [33] . Moreover, similar gaps in PCI and CABG use in AMI treatment have been observed by others comparing data from Sweden, UK and the USA [1, 3, 4, 34, 35] . However, contrary to our results, lower procedure use in Sweden was not associated with increased risk of short-term death when compared to the USA.
We observed significant between-hospital variability in procedure use and in survival across hospitals in Portugal. Such variability indicates a closer positive relationship among discharges of the same hospital and greater heterogeneity between hospitals. Betweenhospital variability in survival was less pronounced but substantially higher in Portugal than in the USA. We also observed this behavior with the extended frailty model [Model 2]. Thus suggesting that hospitals with similar practice patterns have similar survival profiles in the USA, whereas there is considerable variation in AMI survival across hospitals with similar practice patterns in Portugal.
Since the Portuguese healthcare system provides universal coverage through a comprehensive network of hospitals, primary care centers and healthcare providers mainly financed through general taxation, we would expect Portugal to require and to achieve control of disparities across hospitals more easily than the USA, which can be thought of as multiple systems bound to a wider diversity of actors. On the other hand, it supports that governmental programs to monitor hospital quality of care in the USA (e.g. the national hospital public reporting program, https:// www.medicare.gov/hospitalcompare/search.html) and the lack of validated standard definitions of quality indicators in AMI in Europe may have paved the way for such consistent quality of care across hospitals in the USA with unparalleled behavior in Europe [36] . Some of the heterogeneity in survival across hospitals in Portugal might be explained by hospital characteristics such as type of services available and training level of providers [37] [38] [39] . Therefore, understanding these factors and how they relate to AMI management and outcomes is an important next step.
Limitations
This study has several limitations to consider. First, the accuracy and consistency of diagnostic and procedures coding for AMI has been assessed in the USA but has not been assessed in Portugal [20, [40] [41] [42] . However, previously published information compiled from independent data sources (e.g. national registry data and survey data) regarding the incidence of STEMI vs. Non-STEMI and revascularization practice patterns agree with proportions and trends observed in our data [32, 33, 43, 44] . Second, due to coding inaccuracies and limitations of the ICD-9-CM in discriminating hospital procedures limited our comparisons to broader classes of health technologies use, such as coronary stenting (DES or BMS) and PCI (stenting, PTCA or coronary atherectomy) and prevented inclusion of fibrinolysis use in our analysis. Another limitation with claims data is the lack of detailed information about the patient's clinical characteristics, such as coronary anatomy, extent of disease, ejection fraction, surgical risk, pain/door-to-balloon times, which may further help to characterize the two cohorts. Third, although the US sample was obtained through a stratification design that provides nationwide representativeness of hospitals, it is possible that AMI hospitalizations are either over-or under-represented. Forth, agesex-adjusted death rates based on vital statistics data indicate lower AMI mortality in Portugal when compared to the USA [31] . This exposes the possibility that a higher proportion of AMI patients in the USA may not have access to treatments or they might die outside the hospital where treatment was provided. Finally we were unable to analyze the data at the patient level, therefore we could not evaluate readmission rates nor patient transfers across hospitals, both of which would aid in understanding treatment practice patterns. We did observe that patients discharge alive in the USA were more likely to get transferred to another care facility when compared with Portugal (USA: 20% vs. Portugal: 13%, of discharges in 2010), however, excluding these discharges would not significantly affect differences in crude in-hospital mortality between countries.
Conclusions
Our findings support that differences observed in patterns of utilization of revascularization procedures and STEMI burden likely contribute to the unfavorable mortality rates in Portugal. However, inhospital mortality systematically declined in both countries with Portugal facing alarming between-hospital asymmetries-a better understanding of processes of care for these patients is urgently required.
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